This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Acceleron And Celgene Announce Interim Clinical Data For Sotatercept In Patients With End Stage Renal Disease On Hemodialysis At The 2014 National Kidney Foundation Spring Clinical Meeting

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that its collaboration partner, Celgene Corporation, will present interim data from an ongoing phase 2a study of sotatercept in patients with end stage renal disease (ESRD) on hemodialysis at the National Kidney Foundation 2014 Spring Clinical Meeting. The meeting will take place on April 22-26, 2014 at the MGM Grand in Las Vegas, NV.

The data to be presented are from an ongoing phase 2a dose escalation study of sotatercept administered subcutaneously every 28 days to evaluate the pharmacokinetics, safety, tolerability, efficacy, and pharmacodynamics of sotatercept for the correction of anemia in patients with ESRD on hemodialysis. Dr. William Smith of Celgene Corporation, Acceleron’s collaboration partner, will present interim safety, pharmacokinetic and hemoglobin data from the first 28-day dose cycle for two dose groups of sotatercept (0.3 mg/kg and 0.5 mg/kg) versus placebo. Following a single dose in the placebo, sotatercept 0.3 mg/kg and sotatercept 0.5 mg/kg dose groups, peak mean hemoglobin changes observed in the first 28 days were 0.1, 0.5 and 0.8 g/dL, respectively. Adverse events were mostly mild to moderate, unrelated to study drug, and generally consistent with patients’ medical histories. No dose-dependent changes in blood pressure were observed.

The data will be presented in a poster presentation on Wednesday April 23 rd from 6:00 - 7:30 PM PST.

About the Phase 2a Clinical Trial

The Phase 2a clinical trial of sotatercept is designed as a randomized, placebo-controlled single dose and multi-dose, dose escalation study to evaluate the pharmacokinetics, safety, efficacy, tolerability and pharmacodynamics of sotatercept for the correction of anemia in patients with end stage renal disease on hemodialysis. The first dose group evaluated was a single dose of 0.1 mg/kg of sotatercept administered subcutaneously. Subsequent dose groups to be studied are 0.3, 0.5 and 0.7 mg/kg administered subcutaneously once every four weeks for up to eight cycles of treatment. Each dose group will include up to 12 patients randomized at a 3:1 ratio to receive either sotatercept or placebo. The trial is being conducted at sites in the United States and may enroll up to 56 patients. The primary endpoints are pharmacokinetics and safety. Celgene has completed enrollment in the 0.1, 0.3 and 0.5 mg/kg dose groups and is now enrolling patients in the 0.7 mg/kg dose group. Secondary endpoints in the study include effects on hemoglobin and serum markers of bone metabolism. For additional information on this clinical trial, please visit www.clinicaltrials.gov, identifier NCT01146574.

In December, 2013, Celgene initiated a second phase 2 clinical trial of sotatercept in patients with end stage renal disease (ESRD) who are on hemodialysis. This phase 2 clinical trial is designed as a two-part study to assess the safety and efficacy of sotatercept as a therapy to treat anemia and potentially to control the adverse manifestations of chronic kidney disease mineral and bone disorder (CKD-MBD). Part one of the study will enroll up to 60 patients and part two of the study will enroll up to 230 patients. For additional information on this clinical trial, please visit www.clinicaltrials.gov, identifier NCT01999582.

About Chronic Kidney Disease

Chronic Kidney Disease (CKD) is a serious condition characterized by the progressive loss of kidney function and is most often caused by diabetes or high blood pressure. CKD is classified in five stages according to the degree of kidney impairment. End Stage Renal Disease (ESRD), also known as kidney failure, is the most advanced stage of CKD and a life-threatening condition in which patients require a either kidney transplant or dialysis for survival. Anemia, low levels of red blood cells, is a common secondary disorder to Chronic Kidney Disease and worsens with progression of the disease. Disturbance in mineral and bone metabolism, known as Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD), is also a common complication in CKD patients that affects almost all patients who are on dialysis. CKD-MBD can lead to bone abnormalities and/or calcification in soft tissue, especially blood vessels, and is associated with increased morbidity and mortality in CKD patients.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,214.42 -10.15 -0.06%
S&P 500 2,110.74 -3.12 -0.15%
NASDAQ 4,987.89 +20.7530 0.42%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs